This inventor holds 1 USPTO granted patent. Top assignee: Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.v.. Active years: 2018.
Company Filing History:
Years Active: 2018
Title: The Innovations of Mario Wurglics
Introduction
Mario Wurglics is an accomplished inventor based in Bad Homburg, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific receptors in the body. His work is particularly relevant in the treatment of immune-related diseases.
Latest Patents
Wurglics holds a patent for a compound known as (E)-2-(5-((4-methoxy-2-(trifluoromethyl)quinolin-6-yl)methoxy)-2-((4-(trifluoromethyl)benzyl)oxy)-benzylidene) hexanoic acid (MTTB). This compound serves as a selective peroxisome proliferator-activated receptor gamma (PPARγ) antagonist. It is indicated for use in treating systemic inflammation, sepsis, and septic shock. He has 1 patent to his name.
Career Highlights
Wurglics is affiliated with the Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., a leading research institution in applied sciences. His work at this institution has allowed him to focus on innovative solutions in the pharmaceutical industry.
Collaborations
Throughout his career, Wurglics has collaborated with notable professionals in his field, including Michael John Parnham and Manfred Schubert-Zsilavecz. These collaborations have further enhanced the impact of his research and innovations.
Conclusion
Mario Wurglics is a prominent figure in the realm of pharmaceutical inventions, with a focus on compounds that address critical health issues. His contributions continue to influence the treatment of immune-related diseases, showcasing the importance of innovation in medicine.